Skip to main content
Year archive

Purple Biotech Ltd. — 2022 filings

All 48 regulatory filings released by Purple Biotech Ltd. (PPBT) in 2022, sourced directly from the official regulator.

48 Filings
2022 Period
2022 filings (48)
Filing Released Lang
Form F-3 Registration Statement - Draft Renewal of Shelf Prospectus
Regulatory Filings
2022-12-08 English
Form F-3 Registration Statement - Draft Renewal of Shelf Prospectus
Capital/Financing Update
2022-12-08 English
6K:Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
Regulatory Filings
2022-11-15 English
6K:Purple Biotech Presents New Data on Mechanism of Action for CM24 at the AACR Special Conference: Cancer Metastasis
Report Publication Announcement
2022-11-15 English
CORPORATE PRESENTATION-NOVEMBER 2022
Investor Presentation
2022-11-09 English
CORPORATE PRESENTATION-NOVEMBER 2022
Regulatory Filings
2022-11-09 English
Biotech Reports Third Quarter 2022 Financial Results
Interim / Quarterly Report Q3 2022
2022-11-08 English
Biotech Reports Third Quarter 2022 Financial Results
Report Publication Announcement
2022-11-08 English
6K:Purple Biotech Appoints Lior Fhima as Chief Financial Officer
Board/Management Information
2022-11-02 English
6K:Purple Biotech Appoints Lior Fhima as Chief Financial Officer
Report Publication Announcement
2022-11-02 English
results of the Annual General Meeting of Shareholders of the Company held on August 25, 2022
AGM Information
2022-08-27 English
results of the Annual General Meeting of Shareholders of the Company held on August 25, 2022
Declaration of Voting Results & Voting Rights Announcements
2022-08-27 English
Reports Second Quarter 2022 Financial Results
Interim / Quarterly Report H1 2022
2022-08-04 English
Reports Second Quarter 2022 Financial Results
Report Publication Announcement
2022-08-04 English
Notice of annual general meeting that will be held on August 25, 2022 , Proxy Statement
AGM Information
2022-07-18 English
Notice of annual general meeting that will be held on August 25, 2022 , Proxy Statement
AGM Information
2022-07-18 English
Notice of annual general meeting that will be held on August 25, 2022 , Proxy Statement
AGM Information
2022-07-18 English
FORM 6-K- Annual General Meeting of Shareholders will be held on August 25, 2022
AGM Information
2022-07-18 English
FORM 6-K- Annual General Meeting of Shareholders will be held on August 25, 2022
AGM Information
2022-07-18 English
6K:Purple Biotech Announces Executive Leadership Changes
Board/Management Information
2022-07-14 English
6K:Purple Biotech Announces Executive Leadership Changes
Board/Management Information
2022-07-14 English
Company Presentation – June 2022
Investor Presentation
2022-06-06 English
Company Presentation – June 2022
Investor Presentation
2022-06-06 English
6K:Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
Regulatory Filings
2022-05-29 English
6K:Purple Biotech Presents Phase 1 Interim Monotherapy Data for NT219 at ASCO 2022, Demonstrating Encouraging Safety & Efficacy Profile
Report Publication Announcement
2022-05-29 English
A report regarding phase 1 interim monotherapy data for NT219 was published on EDGAR.
Regulatory Filings
2022-05-29 Hebrew (modern)
6K:Initiation of Phase 2 Study for CM24 & dismissal of the BIRAD Lawsuit
Regulatory Filings
2022-05-18 English
6K:Initiation of Phase 2 Study for CM24 & dismissal of the BIRAD Lawsuit
Report Publication Announcement
2022-05-18 English
6K: Purple Biotech Reports First Quarter 2022 Financial Results
Interim / Quarterly Report Q1 2022
2022-05-12 English
6K: Purple Biotech Reports First Quarter 2022 Financial Results
Report Publication Announcement
2022-05-12 English
Dr. Bertrand C. Liang and the Company have mutually agreed to terminate his service as Chief Medical Officer of the Company, to pursue other opportunities, effective May 1, 2022
Regulatory Filings
2022-05-02 English
Dr. Bertrand C. Liang and the Company have mutually agreed to terminate his service as Chief Medical Officer of the Company, to pursue other opportunities, effective May 1, 2022
Regulatory Filings
2022-05-02 English
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting-Complementary Report
Regulatory Filings
2022-04-11 English
Purple Biotech Presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting-Complementary Report
Report Publication Announcement
2022-04-11 English
presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
Regulatory Filings
2022-04-11 English
presents Positive Interim Phase 1b Study Results for CM24 at the American Association of Cancer Research 2022 Annual Meeting
Regulatory Filings
2022-04-11 English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Purple biotech LTD. 2016 EQUITY-BASED INCENTIVE PLAN
Capital/Financing Update
2022-04-04 English
FORM S-8-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Purple biotech LTD. 2016 EQUITY-BASED INCENTIVE PLAN
Capital/Financing Update
2022-04-04 English
prospectus supplement originally filed by the Company with the United States
Capital/Financing Update
2022-03-23 English
prospectus supplement originally filed by the Company with the United States
Capital/Financing Update
2022-03-23 English
Annual report for 2021 on form 20F
Annual Report FY 2021
2022-03-09 English
Annual report for 2021 on form 20F
Report Publication Announcement
2022-03-09 English
results for the year and the six months ended December 31, 2021
Earnings Release FY 2021
2022-02-09 English
results for the year and the six months ended December 31, 2021
Report Publication Announcement
2022-02-09 English
Issues Letter to Shareholders
Investor Presentation
2022-02-05 English
Issues Letter to Shareholders
Report Publication Announcement
2022-02-05 English
6K:Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors
Board/Management Information
2022-01-06 English
6K:Purple Biotech Appoints Life Sciences Industry Investor Ori Hershkovitz to its Board of Directors
Board/Management Information
2022-01-06 English